Welcome to our dedicated page for Aspire Biopharma Holdings news (Ticker: ASBP), a resource for investors and traders seeking the latest updates and insights on Aspire Biopharma Holdings stock.
Aspire Biopharma Holdings Inc (ASBP) delivers cutting-edge sublingual drug delivery solutions designed to transform patient care through rapid-acting formulations. This news hub provides investors and industry professionals with timely updates on regulatory milestones, clinical advancements, and strategic developments.
Access authoritative reporting on ASBP's innovative pipeline, including nanotechnology-enhanced medications for cardiology emergencies, pain management, and hormonal therapies. Track progress on FDA-reviewed products, manufacturing partnerships, and intellectual property expansions that demonstrate the company's scientific leadership.
Our curated news collection features earnings announcements, research breakthroughs, and market analyses relevant to ASBP's mission of improving drug bioavailability. Bookmark this page for direct access to primary-source updates about sublingual delivery innovations shaping the future of biopharmaceuticals.
Aspire Biopharma (NASDAQ:ASBP) has announced positive top-line results from its clinical trial evaluating a new sublingual aspirin product for treating suspected acute myocardial infarction (heart attack). The randomized crossover bioavailability study demonstrated that the sublingual formulation achieved higher and faster plasma concentrations of acetylsalicylic acid compared to standard chewed aspirin tablets.
The trial involved six healthy subjects aged 40-65 years who received 162mg aspirin doses across three treatment periods. The sublingual delivery system offers several advantages, including rapid absorption, faster onset of action, and reduced GI irritation. This development is particularly significant as AMI affects nearly 3 million Americans annually, with 800,000 experiencing heart attacks and 300,000 resulting in deaths.
Aspire Biopharma Holdings (NASDAQ:ASBP), a company developing patent-pending drug and supplement delivery technology, has announced its participation in the upcoming Sidoti Virtual Investor Conference. Interim CEO Kraig Higginson will present on August 20, 2025, at 1:45 PM Eastern.
The company will also host one-on-one meetings with investors on August 20-21, 2025. Investors can access the virtual presentation through Sidoti's registration platform, and a replay will be available on Aspire's investor relations website.
Aspire Biopharma (NASDAQ:ASBP) has successfully launched its innovative pre-workout supplement BUZZ BOMB™ at FitCon and FitExpo, distributing over 30,000 sample packs to attendees. The product features a unique sublingual delivery technology with 50mg of caffeine in four flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha.
The product differentiates itself through rapid absorption (under 2 minutes vs. traditional 20-30 minutes), convenient single-use packets, and precise energy management. Notable fitness figures including UFC fighter Bobby Maximus and MMA champion Brandon Copeland have provided positive testimonials. The product is now available for purchase through the company's e-commerce website buzzbomb.buzz.
Aspire Biopharma Holdings (NASDAQ:ASBP) has launched its new e-commerce platform, buzzbomb.buzz, featuring its innovative product BUZZ BOMB™, a sublingual pre-workout supplement. The product delivers 50mg of caffeine rapidly through a unique under-the-tongue delivery system, available in four flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha.
The new direct-to-consumer platform offers exclusive promotions, including special pricing and free shipping for registered customers. The company is offering both sample packs of all four flavors and 30-pack configurations. To support the launch, Aspire plans to showcase the product at two major fitness conventions in early August.
Aspire Biopharma Holdings (NASDAQ:ASBP) announced significant leadership changes, with Chairman Kraig Higginson appointed as interim CEO effective July 24, 2025, following Michael C. Howe's resignation from both CEO position and Board membership.
The company also announced the immediate resignations of Board members Gary E. Stein and Barbara Sher. In a key appointment, Howard Doss, a seasoned financial executive with extensive experience at companies like PowerUp and Trade Health, has joined as Director and Chairman of the Audit Committee.
Higginson, who previously served as CEO for four years, expressed commitment to executing the company's strategy focused on its drug delivery platform technology.
Aspire Biopharma Holdings (NASDAQ:ASBP) announced the launch of its new pre-workout supplement BUZZ BOMB™ at two major fitness conventions - FitCon in Salt Lake City (August 1-2) and FitExpo in Anaheim (August 2-3, 2025).
The product features 50mg of caffeine delivered through sublingual nano technology, offering nearly instant energy through easy-to-use packets. As a Gold Sponsor at FitCon (20,000 attendees) and sponsor at FitExpo (33,000 attendees), BUZZ BOMB™ will receive prominent placement, extensive marketing exposure, and product sampling opportunities to all attendees.
The company aims to disrupt the multi-billion-dollar pre-workout market with its innovative delivery system that provides immediate effects compared to traditional pre-workout supplements that require 20-30 minutes to activate.
Aspire Biopharma Holdings (NASDAQ:ASBP) has announced positive consumer feedback for its new pre-workout supplement BUZZ BOMB™. The product features a patent-pending sublingual delivery technology with 50mg of caffeine designed for rapid absorption and immediate effect.
The company has completed initial production in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Mocha Coffee) and plans to launch at major fitness conventions in August. BUZZ BOMB™ is packaged in single-serving packets and targets the pre-workout supplement market, projected to reach $27.97 billion by 2030.
CEO Michael Howe indicated this launch represents the first step in Aspire's strategy to leverage its sublingual nano technology, with plans to introduce additional nutraceutical and supplement products while exploring licensing opportunities.
Aspire Biopharma Holdings (NASDAQ:ASBP) has completed patient dosing in its Phase 1 clinical trial for its oral transmucosal fast-acting high-dose aspirin formulation. The study compares the company's sublingual 162.5 mg aspirin powder against traditional oral aspirin in healthy adult volunteers.
The trial evaluates plasma acetylsalicylic acid concentration, Arachidonic acid-induced platelet aggregation, and Serum thromboxane B2 measurements to assess the formulation's rapid impact on cardiac events. Topline results are expected by mid-Q3 2025, after which Aspire plans to pursue a section 505(b)(2) NDA and explore potential partnership opportunities.
FAQ
What is the current stock price of Aspire Biopharma Holdings (ASBP)?
What is the market cap of Aspire Biopharma Holdings (ASBP)?
